General Information of Drug (ID: DMD4YRG)

Drug Name
EQ-917 Drug Info
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 2 [1]
Cross-matching ID
TTD Drug ID
DMD4YRG

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug(s) Targeting DNA topoisomerase I (TOP1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Irinotecan DMP6SC2 Adenocarcinoma 2D40 Approved [3]
Topotecan DMP6G8T Central nervous system neoplasm Approved [3]
B-Lactams DMR8YD6 Bacterial infection 1A00-1C4Z Approved [4]
Belotecan hydrocholoride DM3SRJZ Small-cell lung cancer 2C25.Y Approved [5]
Topetecan DMAE6LK Small-cell lung cancer 2C25.Y Approved [6]
Karenitecin DMCRGY4 Lung cancer 2C25.0 Phase 3 [7]
Camptothecin DM6CHNJ Solid tumour/cancer 2A00-2F9Z Phase 3 [8]
Exatecan DMCA7FN Solid tumour/cancer 2A00-2F9Z Phase 3 [9]
Edotecarin DM3ZL7D Gastric adenocarcinoma 2B72 Phase 3 [10]
Rubitecan DMDWU1S Human immunodeficiency virus infection 1C62 Phase 3 [11]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
DNA topoisomerase I (TOP1) TTGTQHC TOP1_HUMAN Inhibitor [2]

References

1 Phase II study of camtobell inj. (belotecan) in combination with cisplatin in patients with previously untreated, extensive stage small cell lung cancer. Lung Cancer. 2013 Jun;80(3):313-8.
2 The efficacy and toxicity of belotecan (CKD-602), a camptothericin analogue topoisomerase I inhibitor, in patients with recurrent or refractory epithelial ovarian cancer. J Chemother. 2010 Jun;22(3):197-200.
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
4 Luteolin, an emerging anti-cancer flavonoid, poisons eukaryotic DNA topoisomerase I. Biochem J. 2002 Sep 1;366(Pt 2):653-61.
5 Impact of natural products on developing new anti-cancer agents. Chem Rev. 2009 Jul;109(7):3012-43.
6 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
7 Characterization of protein kinase chk1 essential for the cell cycle checkpoint after exposure of human head and neck carcinoma A253 cells to a novel topoisomerase I inhibitor BNP1350. Mol Pharmacol.2000 Mar;57(3):453-9.
8 Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer. 2006 Oct;6(10):789-802.
9 Phase I study of topoisomerase I inhibitor exatecan mesylate (DX-8951f) given as weekly 24-hour infusions three of every four weeks. Clin Cancer Res. 2001 Dec;7(12):3963-70.
10 Edotecarin: a novel topoisomerase I inhibitor. Clin Colorectal Cancer. 2005 May;5(1):27-36.
11 Rubitecan. Expert Opin Investig Drugs. 2006 Jan;15(1):71-9.